Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992;29(6):475-9.
doi: 10.1007/BF00684851.

Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

Affiliations
Comparative Study

Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

A Haldane et al. Cancer Chemother Pharmacol. 1992.

Abstract

The cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601,316), a new experimental DNA-intercalating antitumor drug, against a cultured Lewis lung adenocarcinoma cell line was compared with that of the DNA-intercalating antitumor drug amsacrine. In contrast to amsacrine, AC demonstrated self-inhibition of cytotoxicity following short (3-9 h) incubation periods and exponential killing (with a shoulder) after long (24-72 h) periods of incubation. The difference between these drugs was best demonstrated using a constant concentration x time (C x T) exposure (AC, 12 mumol h l-1; amsacrine, 3 mumol h l-1). In contrast to amsacrine, AC was minimally effective over exposure periods of less than or equal to 1 h and maximally effective over intermediate periods (4-6 h). The results suggest the possibility of designing AC administration protocols that maximise the drug's cytotoxicity towards solid tumors, which, because of diffusion barriers, are subjected to longer drug exposures than are well-vascularised tumours.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Cancer. 1974 Aug;10 (8):539-49 - PubMed
    1. Cancer Chemother Pharmacol. 1988;21(3):185-90 - PubMed
    1. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1783-90 - PubMed
    1. Cancer Res. 1982 May;42(5):1641-5 - PubMed
    1. Eur J Cancer Clin Oncol. 1989 Dec;25(12 ):1695-701 - PubMed

Publication types

MeSH terms

LinkOut - more resources